These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32530884)

  • 1. Urinary Buprenorphine, Norbuprenorphine and Naloxone Concentrations and Ratios: Review and Potential Clinical Implications.
    Warrington JS; Warrington GS; Francis-Fath S; Brooklyn J
    J Addict Med; 2020 Dec; 14(6):e344-e349. PubMed ID: 32530884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of free (unconjugated) buprenorphine, norbuprenorphine, and their glucuronides in urine using liquid chromatography-tandem mass spectrometry.
    McMillin GA; Davis R; Carlisle H; Clark C; Marin SJ; Moody DE
    J Anal Toxicol; 2012 Mar; 36(2):81-7. PubMed ID: 22337776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of Buprenorphine, Norbuprenorphine, Buprenorphine Glucuronide, Norbuprenorphine Glucuronide, and Naloxone in Urine by LC-MS/MS.
    Marin SJ; McMillin GA
    Methods Mol Biol; 2016; 1383():69-78. PubMed ID: 26660175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine, Norbuprenorphine, and Naloxone Levels in Adulterated Urine Samples: Can They be Detected When Buprenorphine/Naloxone Film is Dipped into Urine or Water?
    Furo H; Whitted M; Lin T; Zhou YY; Abdelsayed S; Brimhall BB; Elkin PL
    Subst Use; 2024; 18():11782218231223673. PubMed ID: 38433747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of urinary naloxone levels in a single provider practice: a case study.
    Warrington JS; Booth K; Warrington GS; Francis-Fath S
    Addict Sci Clin Pract; 2020 Jan; 15(1):3. PubMed ID: 31941557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine naloxone concentration at different phases of buprenorphine maintenance treatment.
    Heikman P; Häkkinen M; Gergov M; Ojanperä I
    Drug Test Anal; 2014 Mar; 6(3):220-5. PubMed ID: 23512803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of buprenorphine-related deaths using urinary metabolite concentrations.
    Mariottini C; Kriikku P; Ojanperä I
    Drug Test Anal; 2022 Oct; 14(10):1696-1702. PubMed ID: 35834288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary detection times and metabolite/parent compound ratios after a single dose of buprenorphine.
    Kronstrand R; Nyström I; Andersson M; Gunnarsson L; Hägg S; Josefsson M; Ahlner J
    J Anal Toxicol; 2008 Oct; 32(8):586-93. PubMed ID: 19007507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies.
    Moody DE; Slawson MH; Strain EC; Laycock JD; Spanbauer AC; Foltz RL
    Anal Biochem; 2002 Jul; 306(1):31-9. PubMed ID: 12069411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio.
    Accurso AJ; Lee JD; McNeely J
    J Subst Abuse Treat; 2017 Dec; 83():62-67. PubMed ID: 29129197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry.
    Liu Y; Li X; Xu A; Nasser AF; Heidbreder C
    J Pharm Biomed Anal; 2016 Feb; 120():142-52. PubMed ID: 26730511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment.
    Suzuki J; Zinser J; Issa M; Rodriguez C
    Subst Abus; 2017; 38(4):504-507. PubMed ID: 28723256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice.
    Donroe JH; Holt SR; O'Connor PG; Sukumar N; Tetrault JM
    Drug Alcohol Depend; 2017 Nov; 180():46-51. PubMed ID: 28866369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of buprenorphine, norbuprenorphine, naloxone, and their glucuronides in urine by liquid chromatography-tandem mass spectrometry.
    Mariottini C; Gergov M; Ojanperä I
    Drug Test Anal; 2021 Sep; 13(9):1658-1667. PubMed ID: 34047070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LC-MS-MS analysis of buprenorphine and norbuprenorphine in whole blood from suspected drug users.
    Seldén T; Roman M; Druid H; Kronstrand R
    Forensic Sci Int; 2011 Jun; 209(1-3):113-9. PubMed ID: 21306845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary buprenorphine concentrations in patients treated with suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay.
    Hull MJ; Bierer MF; Griggs DA; Long WH; Nixon AL; Flood JG
    J Anal Toxicol; 2008 Sep; 32(7):516-21. PubMed ID: 18713521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine is superior to oral fluid for detecting buprenorphine compliance in patients undergoing treatment for opioid addiction.
    Ransohoff JR; Petrides AK; Piscitello GJ; Flood JG; Melanson SEF
    Drug Alcohol Depend; 2019 Oct; 203():8-12. PubMed ID: 31394416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of Buprenorphine and Norbuprenorphine in Urine.
    Terrell AR; Adhlakha V; Reddy P
    Methods Mol Biol; 2019; 1872():51-59. PubMed ID: 30350278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program.
    Furo H; Schwartz DG; Sullivan RW; Elkin PL
    Subst Abuse; 2021; 15():11782218211061749. PubMed ID: 34898987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of buprenorphine, norbuprenorphine and naloxone in fingernail clippings and urine of patients under opioid substitution therapy.
    Tzatzarakis MN; Vakonaki E; Kovatsi L; Belivanis S; Mantsi M; Alegakis A; Liesivuori J; Tsatsakis AM
    J Anal Toxicol; 2015 May; 39(4):313-20. PubMed ID: 25663675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.